Welcome to our dedicated page for Theralink Technologies news (Ticker: THER), a resource for investors and traders seeking the latest updates and insights on Theralink Technologies stock.
Theralink Technologies, Inc. (symbol: THER) is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer immunotherapy products. With a focus on prostate and breast cancers, the company leverages its proprietary immunotherapy platform to pioneer new treatments in the oncology sector.
Theralink's lead product, ProscaVax, is currently in phase 2 clinical trials for the treatment of prostate cancer, showcasing promising potential in its early stages. In addition to ProscaVax, the company is actively developing targeted therapies to enhance their oncology portfolio.
In partnership with Perthera, Inc., Theralink aims to facilitate and enhance access to its proprietary 32 phosphoprotein panel, known as the Theralink Assay, specifically for breast cancer patients. This partnership is a strategic move to expand their impact and reach within the cancer treatment landscape.
Established in Baton Rouge, Louisiana, Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. before rebranding in September 2020 to better reflect its innovative approach and expanded focus.
Theralink Technologies (OTC: THER) announced the acceptance of two poster presentations at the San Antonio Breast Cancer Symposium (SABCS) 2022 focused on its innovative RPPA (Reverse Phase Protein Array) technology. The presentations will explore the utility of the Theralink Assay in enhancing clinical molecular profiling of breast cancer patients. CEO Mick Ruxin emphasized the importance of accurate HER2 status determination, particularly for patients with HER2 Low metastatic breast cancer. Details of the poster presentations are available on the SABCS website.
Theralink Technologies (OTC: THER) announced a private placement of senior secured convertible debentures and warrants, generating approximately $3.1 million in gross proceeds. The debentures have a principal amount of $3.4 million, with a 10% interest rate over 12 months. Investors will receive securities convertible at a discount in future financings. Existing convertible securities totaling $13.4 million will also convert into debentures. The offering is limited to accredited investors and will not be registered under the Securities Act.
Theralink Technologies (OTC: THER) has achieved College of American Pathologists (CAP) accreditation for its Reverse Phase Protein Array laboratory in Golden, Colorado. This accreditation signifies adherence to the highest laboratory standards following a thorough inspection. CEO Mick Ruxin highlighted this milestone as it positions Theralink as the only commercial laboratory in the U.S. with CAP accreditation for Next Generation Proteomic services. In addition, Theralink's laboratory is CLIA-certified, which underscores its compliance with clinical testing standards, potentially benefiting cancer patients.
Theralink Technologies (OTC: THER) has announced a significant advancement with the final determination of the Medicare reimbursement rate and completion of the Medicare enrollment process, including obtaining a Provider Transaction Access Number (PTAN). This milestone aims to broaden patient access to the Theralink Assay for advanced breast cancer, which analyzes individual patient biology for improved therapy selection. Initial studies show over 90% actionability and more than 75% clinical utility, indicating strong potential for clinical application.
Theralink Technologies (OTC: THER) has appointed Dr. Mattia Cremona as the Director of its Biopharma Laboratory, effective November 7, 2022. Dr. Cremona, renowned for his work in translational oncology research and Reverse Phase Protein Array Technology, aims to enhance Theralink’s precision oncology capabilities. With a PhD in Molecular Medicine and a background in proteomic research, he is expected to help improve patient outcomes by better predicting responses to cancer therapies. Theralink continues to develop innovative assays to assist oncologists and pharmaceutical companies in the treatment of various cancers.
Theralink Technologies (OTC: THER), a precision medicine company specializing in cancer diagnostics, announced the participation of Dr. Mick Ruxin, CEO, at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The conference will be held at the Lotte New York Palace and virtually, with presentations available on demand starting September 12 at 7:00 a.m. ET. Dr. Ruxin will also hold one-on-one investor meetings. Theralink's innovative phosphoprotein-based assays aim to improve cancer treatment outcomes by aiding in the identification of effective therapies.
Theralink Technologies has expanded its patent portfolio to nine with the acquisition of two U.S. patents from George Mason University related to methods for treating breast cancer. These patents enhance Theralink's predictive biomarker capabilities, allowing for improved identification of patients likely to respond to therapies, particularly concerning PARP inhibitors and HER2-EGFR inhibitors. The patents aim to increase treatment suitability for the majority of breast cancer patients, thereby advancing precision oncology and potentially improving outcomes for patients.
Theralink Technologies (OTC: THER) will host a virtual fireside chat with President & CEO Mick Ruxin on June 22, 2022, at 11:00 AM ET. The discussion will center on precision oncology technologies and their impact on breast cancer treatment, alongside Theralink’s recent milestones and future strategies. The company specializes in phosphoprotein-based assays aimed at enhancing cancer outcomes and assisting oncologists.
To participate, register here.
Theralink Technologies (OTC: THER) has expanded the adoption of its precision medicine technology, including Laser Capture Microdissection and Reverse Phase Protein Array, to 18 biopharmaceutical clients, supporting 41 studies. The company is in talks to develop Companion Diagnostics, essential for targeted cancer treatments. CEO Mick Ruxin highlighted the value of their patented technology in expediting drug development and minimizing costs. Theralink's assays aim to improve cancer patient outcomes and support drug development through precise molecular profiling.
Theralink Technologies (OTC: THER) and Avera Health have announced a strategic collaboration aimed at enhancing precision oncology through comprehensive molecular profiling. This partnership will utilize Theralink's patented RPPA technology to provide detailed insights into activated protein drug targets in cancer patients. By integrating this data with genomic findings, Avera aims to improve treatment personalization for oncology patients. The collaboration may also extend Theralink's assay capabilities to other tumor types, potentially broadening its application in precision oncology.
FAQ
What is the current stock price of Theralink Technologies (THER)?
What is the market cap of Theralink Technologies (THER)?
What does Theralink Technologies, Inc. specialize in?
What is ProscaVax?
Which types of cancer does Theralink focus on?
What is the Theralink Assay?
Who is Theralink's partner?
Where is Theralink Technologies, Inc. located?
What was Theralink Technologies, Inc. formerly known as?
What stage are the clinical trials for ProscaVax in?
Does Theralink Technologies develop other therapies?
How does Theralink aim to impact cancer treatment?
